Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 390 participants.

Also called NCT05934526

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 390 participants (enrolled count) (from the registry)
Sponsor
GB002, Inc. (from the registry)
Registry
  • NCT NCT05934526
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Czechia, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Japan, Latvia, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Saudi Arabia, Serbia, Singapore, South Korea, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05934526. Randomized; double masking; primary purpose treatment. Start 2023-12-28 (actual); primary completion 2025-11-27 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Condition
Pulmonary Arterial Hypertension
Intervention (Drug)
Placebo
Intervention (Drug)
Seralutinib
Intervention (Device)
Generic Dry Powder Inhaler
Lead sponsor
GB002, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05934526
Content hash
64c323eccb784e530cd0c8aa09336f28ae18284e865494226726c68eefcbfb08